SLC5A2 and metabolic dysfunction-associated steatohepatitis: In addition, by reducing fat mass, SGLT2 inhibitors prevent the release of inflammatory cytokines by adipocytes, thus decreasing the inflammatory effect, which is one of the main causes of NASH progression [80].